CAJ | 학술논문

目的：观察替吉奥联合伊力替康、多西紫杉醇等化疗方案治疗晚期胃癌的疗效及安全性。方法回顾性分析晚期胃癌患者43例，分为两组：每组替吉奥的剂量均根据体表面积来确定初始剂量，体表面积＜1.25m2，替吉奥40mg/次，2次/日；体表面积1.25～1.5m2，替吉奥50mg/次，2次/日；体表面积＞1.5m2，替吉奥60mg/次，2次/日，早、晚饭后口服，连续服用14天，停药7天。A 组20例：替吉奥+紫杉醇+伊力替康（紫杉醇90mg /m2，静脉滴注3小时，第1、8天，伊力替康180mg/m2，静脉滴注90分钟，第2，9天）。B 组23例：替吉奥+多西紫杉醇+奥沙利铂（多西紫杉醇60mg /m2，静脉滴注1小时，第1，8天，奥沙利铂130 mg /m2，静脉滴注3小时，第2，9天）；每组均21天为一周期，两个周期后评价疗效，每周期评价毒副反应。结果全部患者均可评价疗效，无治疗相关性死亡事件发生。两组客观有效率(ORR)分别为：50.0%（10/20），52.3%（11/23）；疾病控制率( DCR)分别为：85.0%（17/20），86.9%（20/23）。不良反应主要是骨髓抑制，胃肠道反应及外周神经毒性。结论替吉奥联合伊力替康、多西紫杉醇等化疗方案治疗晚期胃癌疗效较高，毒副反应较轻，多数患者耐受性良好，值得扩大样本进一步研究。
목적：관찰체길오연합이력체강、다서자삼순등화료방안치료만기위암적료효급안전성。방법회고성분석만기위암환자43례，분위량조：매조체길오적제량균근거체표면적래학정초시제량，체표면적＜1.25m2，체길오40mg/차，2차/일；체표면적1.25～1.5m2，체길오50mg/차，2차/일；체표면적＞1.5m2，체길오60mg/차，2차/일，조、만반후구복，련속복용14천，정약7천。A 조20례：체길오+자삼순+이력체강（자삼순90mg /m2，정맥적주3소시，제1、8천，이력체강180mg/m2，정맥적주90분종，제2，9천）。B 조23례：체길오+다서자삼순+오사리박（다서자삼순60mg /m2，정맥적주1소시，제1，8천，오사리박130 mg /m2，정맥적주3소시，제2，9천）；매조균21천위일주기，량개주기후평개료효，매주기평개독부반응。결과전부환자균가평개료효，무치료상관성사망사건발생。량조객관유효솔(ORR)분별위：50.0%（10/20），52.3%（11/23）；질병공제솔( DCR)분별위：85.0%（17/20），86.9%（20/23）。불량반응주요시골수억제，위장도반응급외주신경독성。결론체길오연합이력체강、다서자삼순등화료방안치료만기위암료효교고，독부반응교경，다수환자내수성량호，치득확대양본진일보연구。
Objective To evaluate the efficiency and toxicity of S-1 combined with CPT-11 or Docetaxel、etc on patients with advanced gastric cancer. Methods Forty-three patients with advanced gastric cancer were divided into two groups:in every group, S-1 was administered based on patients' body surface area: <1.25m2,40mg,bid; 1.25~1.5m2, 50mg, bid; >1.5m2, 60mg, bid,d1- 14. group A with 20 patients(S-1 + PTX + CPT-11, PTX 90mg/m2 iv,d1,8; CPT-11 180mg/m2 iv,d2,9),group B with 23patients(S-1 + DTX + L-OHP,DTX 60mg /m2 iv,d1,8;L-OHP 130mg/m2 iv,d2,9). Twenty-one days was a cycle. The evaluation of efficacy and toxicity was performed after 2courses. Results The overall response rates (ORR) were50.0%(10/20),52.3%(11/23); and the disease control rate(DCR)were 85.0%(17/20),86.9%(20/23), respectively. The major toxicities included leucopenia,nause,vomiting and neurosensory abnormity. No occurrence of treatment related deaths was observed. Conclusion The regimen of S-1 combined with CPT-11 or Docetaxel、etc is effective and tolerable in toxic effects for patients with advanced gastric cancer, which is worth being further studied in the future in clinic.